ATE350038T1 - Pharmazeutische zubereitungen enthaltend nanopartikel von 2-(4-ethoxy-phenyl)-3-(4- methansulphonyl-phenyl)-pyrazolo 1,5-böpyridazi - Google Patents

Pharmazeutische zubereitungen enthaltend nanopartikel von 2-(4-ethoxy-phenyl)-3-(4- methansulphonyl-phenyl)-pyrazolo 1,5-böpyridazi

Info

Publication number
ATE350038T1
ATE350038T1 AT03706615T AT03706615T ATE350038T1 AT E350038 T1 ATE350038 T1 AT E350038T1 AT 03706615 T AT03706615 T AT 03706615T AT 03706615 T AT03706615 T AT 03706615T AT E350038 T1 ATE350038 T1 AT E350038T1
Authority
AT
Austria
Prior art keywords
phenyl
böpyridazi
methanesulphonyl
pyrazolo
ethoxy
Prior art date
Application number
AT03706615T
Other languages
English (en)
Inventor
Jonathan Appleby
Martin Rolfe Hill
Simon Joseph Holland
Stephanie Lynn Pearson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE350038T1 publication Critical patent/ATE350038T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT03706615T 2002-03-15 2003-03-13 Pharmazeutische zubereitungen enthaltend nanopartikel von 2-(4-ethoxy-phenyl)-3-(4- methansulphonyl-phenyl)-pyrazolo 1,5-böpyridazi ATE350038T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0206200.8A GB0206200D0 (en) 2002-03-15 2002-03-15 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ATE350038T1 true ATE350038T1 (de) 2007-01-15

Family

ID=9933079

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03706615T ATE350038T1 (de) 2002-03-15 2003-03-13 Pharmazeutische zubereitungen enthaltend nanopartikel von 2-(4-ethoxy-phenyl)-3-(4- methansulphonyl-phenyl)-pyrazolo 1,5-böpyridazi

Country Status (21)

Country Link
US (1) US20050153967A1 (de)
EP (1) EP1485098B1 (de)
JP (1) JP2005520824A (de)
KR (1) KR20040091133A (de)
CN (1) CN1642549A (de)
AT (1) ATE350038T1 (de)
AU (1) AU2003208709A1 (de)
BR (1) BR0307427A (de)
CA (1) CA2478758A1 (de)
DE (1) DE60310896T2 (de)
EA (1) EA007201B1 (de)
EC (1) ECSP045295A (de)
ES (1) ES2277634T3 (de)
GB (2) GB0206200D0 (de)
IS (1) IS7378A (de)
MX (1) MXPA04009008A (de)
NO (1) NO20043889L (de)
NZ (1) NZ534179A (de)
PL (1) PL372932A1 (de)
WO (1) WO2003077920A1 (de)
ZA (1) ZA200406553B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60305053T2 (de) 2002-08-19 2006-08-31 Glaxo Group Ltd., Greenford Pyrimidinderivate als selektive cox-2-inhibitoren
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
KR100382619B1 (ko) * 1997-09-05 2003-05-09 글락소 그룹 리미티드 2,3-디아릴-피라졸로[1,5-b]피리다진 유도체, 그의 제조방법 및 시클로옥시게나제 2(cox-2) 억제제로서의 용도
ES2236007T3 (es) * 1999-12-08 2005-07-16 Pharmacia Corporation Composiciones de inhibidor de ciclooxigenasa-2 ue tiene un efecto terapeutico rapido.
CZ303572B6 (cs) * 2000-06-28 2012-12-12 Smithkline Beecham P. L. C. Jemne rozmelnený prostredek a zpusob jeho prípravy

Also Published As

Publication number Publication date
ECSP045295A (es) 2004-10-26
MXPA04009008A (es) 2004-12-07
GB2402335A (en) 2004-12-08
DE60310896T2 (de) 2007-05-10
US20050153967A1 (en) 2005-07-14
NO20043889L (no) 2004-09-16
WO2003077920A1 (en) 2003-09-25
ES2277634T3 (es) 2007-07-16
EP1485098B1 (de) 2007-01-03
KR20040091133A (ko) 2004-10-27
ZA200406553B (en) 2005-09-22
GB2402335B (en) 2005-10-12
GB0206200D0 (en) 2002-05-01
DE60310896D1 (de) 2007-02-15
AU2003208709A1 (en) 2003-09-29
JP2005520824A (ja) 2005-07-14
IS7378A (is) 2004-07-29
PL372932A1 (en) 2005-08-08
GB0419971D0 (en) 2004-10-13
EA200400864A1 (ru) 2005-02-24
CN1642549A (zh) 2005-07-20
EA007201B1 (ru) 2006-08-25
EP1485098A1 (de) 2004-12-15
BR0307427A (pt) 2004-12-28
CA2478758A1 (en) 2003-09-25
NZ534179A (en) 2006-07-28

Similar Documents

Publication Publication Date Title
ES2545205T3 (es) Combinación de azelastina y ciclesonida
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
EA200500853A1 (ru) 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
EA200200571A1 (ru) Новая композиция и ее применение
CY1108874T1 (el) ΧΡΗΣΗ ΤΩΝ ΑΝΑΣΤΟΛΕΩΝ Ι κΒ- ΚΙΝΑΣΗΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΠΟΝΟΥ
ES2178943B1 (es) Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica.
GEP20074123B (en) Amino acids with affinity for the alpha−2−delta−protein
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
EA200200119A1 (ru) β-КАРБОЛИНОВЫЕ ЛЕКАРСТВЕННЫЕ ПРОДУКТЫ
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DE60137069D1 (de) Arzneizusammensetzungen enthaltend modafinilverbindungen
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
SE9902935D0 (sv) Pharmaceutical compositions
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
ATE350038T1 (de) Pharmazeutische zubereitungen enthaltend nanopartikel von 2-(4-ethoxy-phenyl)-3-(4- methansulphonyl-phenyl)-pyrazolo 1,5-böpyridazi
SE9902937D0 (sv) Pharmaceutical compositions
DE60212710D1 (de) Pharmazeutische zubereitungen enthaltend epothilone und deren verwendung bei der behandlung von karzinoid
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
WO2002057246A3 (en) Inhibitors of cruzipain and other cysteine proteases
SE9902742D0 (sv) New pharmaceutical formultion
WO2002057248A3 (en) Inhibitors of cruzipain and other cysteine proteases
AR038847A1 (es) Uso del compuesto n-(3,5-dicloro-2-metoxi-fenil) -4-metoxi-3-piperazin-1-il-bencenosulfonamida para la elaboracion de una composicion farmaceutica y dicha composicion farmaceutica
DE69413302T2 (de) Palau'amin: eine pharmakologisch aktive Verbindung aus einem Schwamm
TR199903001T2 (xx) 2-{4-$4-(4,5-Dikloro-2-metilimidazol-1-YL) Butil]-1-piperazinil}-5-floropirimidin, haz�rlan��� ve tedavi edici olarak kullan�m�.
DE50304524D1 (de) Arzneimittel enthaltend substituierte 2,5-diaminomethyl-1h-pyrrole

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties